CBP modulates sensitivity to dasatinib in pre-BCR+ acute lymphoblastic leukemia

Dasatinib is a multi-tyrosine kinase inhibitor approved for treatment of Ph+ acute lymphoblastic leukemia (ALL), but its efficacy is limited by resistance. Recent preclinical studies suggest that dasatinib may be a candidate therapy in additional ALL subtypes including pre-BCR+ ALL. Here we utilized...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Cancer Res
Auteurs principaux: Duque-Afonso, Jesús, Lin, Chiou-Hong, Han, Kyuho, Morgens, David W., Jeng, Edwin E., Weng, Ziming, Jeong, Johan, Wong, Stephen Hon Kit, Zhu, Li, Wei, Michael C., Chae, Hee-Don, Schrappe, Martin, Cario, Gunnar, Duyster, Justus, Xiao, Xiangshu, Sakamoto, Kathleen M., Bassik, Michael C., Cleary, Michael L.
Format: Artigo
Langue:Inglês
Publié: 2018
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6283070/
https://ncbi.nlm.nih.gov/pubmed/30262461
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-18-1703
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires